These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 7204884)

  • 1. Hormone secretion by cell culture of human GH-PRL secreting pituitary adenomas: effects of bromocriptine.
    Lei T; Bai X; Liu K; Hu W; Xue D; Jiang X
    J Tongji Med Univ; 1998; 18(3):161-3. PubMed ID: 10806816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations.
    Dumitriu-Stan RI; Burcea IF; Nastase VN; Ceaușu RA; Dumitrascu A; Cocosila LC; Bastian A; Zurac S; Raica M; Poiana C
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences between GH and PRL co-secreting and GH-secreting pituitary adenomas. A series of 604 cases.
    Araujo-Castro M; Biagetti B; Menéndez Torre E; Novoa-Testa I; Cordido F; Pascual Corrales E; Rodríguez Berrocal V; Guerrero-Pérez F; Vicente A; Percovich JC; García Centeno R; González L; Ollero García MD; Irigaray Echarri A; Moure Rodríguez MD; Novo-Rodríguez C; Calatayud M; Villar R; Bernabéu I; Alvarez-Escola C; Benítez Valderrama P; Tenorio-Jimenéz C; Abellán Galiana P; Venegas Moreno E; González Molero I; Iglesias P; Blanco C; Vidal-Ostos De Lara F; de Miguel P; López Mezquita E; Hanzu F; Aldecoa I; Lamas C; Aznar S; Aulinas A; Calabrese A; Gracia P; Recio-Córdova JM; Aviles M; Asensio-Wandosel D; Sampedro M; Ruz-Caracuel I; Camara R; Paja M; Fajardo-Montañana C; Marazuela M; Puig-Domingo M
    J Clin Endocrinol Metab; 2024 Mar; ():. PubMed ID: 38436926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term morphologic and functional effects of bromocriptine on pituitary prolactin cell adenomas in vitro.
    Asa SL; Kovacs R; Kovacs K
    Endocr Pathol; 1993 Jun; 4(2):79-85. PubMed ID: 32370447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete Shrinking of Mixed Growth Hormone and Prolactin-Secreting Pituitary Adenoma With Bromocriptine Therapy Alone.
    Fan J; Shen H; Mo J; Zhang J
    J Craniofac Surg; 2024 May; ():. PubMed ID: 38710062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Tamoxifen on the Management of Dopamine Agonist-Resistant Prolactinomas: A Systematic Review.
    Bazuhair T; Aleid B; Almalki M
    Cureus; 2023 Feb; 15(2):e35171. PubMed ID: 36950000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refractory lactotroph adenomas.
    Urwyler SA; Karavitaki N
    Pituitary; 2023 Jun; 26(3):273-277. PubMed ID: 36928728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen Exerts Anticancer Effects on Pituitary Adenoma Progression via Inducing Cell Apoptosis and Inhibiting Cell Migration.
    Lv T; Zhang Z; Yu H; Ren S; Wang J; Li S; Sun L
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Aggressive Pituitary Adenomas at the Molecular Level-A Review.
    Voellger B; Zhang Z; Benzel J; Wang J; Lei T; Nimsky C; Bartsch JW
    J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening and Identification of Differential Ovarian Proteins before and after Induced Ovulation via Seminal Plasma in Bactrian Camels.
    Wang Q; Zhang Q; Li Y; Zhao X; Zhang Y
    Animals (Basel); 2021 Dec; 11(12):. PubMed ID: 34944287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA‑29‑3p regulates the β‑catenin pathway by targeting IGF1 to inhibit the proliferation of prolactinoma cells.
    Xia J; Li S; Ma D; Guo W; Long H; Yin W
    Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33846792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine agonist resistant prolactinomas: any alternative medical treatment?
    Souteiro P; Karavitaki N
    Pituitary; 2020 Feb; 23(1):27-37. PubMed ID: 31522358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical therapy: options and uses.
    Carmichael JD; Bonert VS
    Rev Endocr Metab Disord; 2008 Mar; 9(1):71-81. PubMed ID: 18163211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas.
    Heaney AP; Fernando M; Melmed S
    J Clin Invest; 2003 May; 111(9):1381-8. PubMed ID: 12727930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional role of estrogen in pituitary tumor pathogenesis.
    Heaney AP; Fernando M; Melmed S
    J Clin Invest; 2002 Jan; 109(2):277-83. PubMed ID: 11805140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nocturnal prolactin secretion in carpal tunnel syndrome.
    Rossi E; Sighinolfi E; Bortolotti P; De Santis G; Schoenhuber R; Grandi M; Landi A
    Ital J Neurol Sci; 1984 Dec; 5(4):405-8. PubMed ID: 6530362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of tamoxifen on GH and PRL secretion by human pituitary tumors.
    Lamberts SW; de Quijada M; Klijn JG
    J Endocrinol Invest; 1980; 3(4):343-7. PubMed ID: 7204884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas.
    Lamberts SW; Verleun T; Oosterom R
    Neuroendocrinology; 1982; 34(5):339-42. PubMed ID: 7078703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
    Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.